These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 26446770

  • 1. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
    Eastell R, Dijk DJ, Small M, Greenwood A, Sharpe J, Yamada H, Yuba M, Tanimoto M, Deacon S.
    Osteoporos Int; 2016 Jan; 27(1):309-18. PubMed ID: 26446770
    [Abstract] [Full Text] [Related]

  • 2. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.
    Nagase S, Hashimoto Y, Small M, Ohyama M, Kuwayama T, Deacon S.
    Br J Clin Pharmacol; 2012 Dec; 74(6):959-70. PubMed ID: 22533981
    [Abstract] [Full Text] [Related]

  • 3. An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women.
    Tanaka M, Hashimoto Y, Hasegawa C.
    Bone; 2015 Dec; 81():178-185. PubMed ID: 26188109
    [Abstract] [Full Text] [Related]

  • 4. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
    Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, Kuwayama T, Deacon S.
    J Bone Miner Res; 2014 Feb; 29(2):458-66. PubMed ID: 23873670
    [Abstract] [Full Text] [Related]

  • 5. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
    Tanaka M, Hashimoto Y, Hasegawa C, Deacon S, Eastell R.
    BMC Musculoskelet Disord; 2017 Jun 19; 18(1):267. PubMed ID: 28629344
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
    Nagase S, Ohyama M, Hashimoto Y, Small M, Kuwayama T, Deacon S.
    J Clin Pharmacol; 2012 Mar 19; 52(3):306-18. PubMed ID: 21719717
    [Abstract] [Full Text] [Related]

  • 7. Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
    Nagase S, Ohyama M, Hashimoto Y, Small M, Sharpe J, Manako J, Kuwayama T, Deacon S.
    J Bone Miner Metab; 2015 Jan 19; 33(1):93-100. PubMed ID: 24458199
    [Abstract] [Full Text] [Related]

  • 8. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D, Luchavova M, Zikan V, Raska I, Kubena AA, Stepan JJ.
    Osteoporos Int; 2012 Dec 19; 23(12):2885-91. PubMed ID: 22426952
    [Abstract] [Full Text] [Related]

  • 9. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
    Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A, Hashimoto Y, Tanaka M, Sugitani M, Kawabata K.
    Bone; 2011 Dec 19; 49(6):1351-6. PubMed ID: 21982869
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study.
    Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S.
    J Bone Miner Res; 2011 Jun 19; 26(6):1303-12. PubMed ID: 21312264
    [Abstract] [Full Text] [Related]

  • 11. Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.
    Hasegawa C, Kastrissios H, Monteleone J, Ohno T, Umemura T, Ohyama M, Nagase S, Small M, Deacon S, Ogawa M, Ieiri I.
    J Clin Pharmacol; 2014 Aug 19; 54(8):937-48. PubMed ID: 24615681
    [Abstract] [Full Text] [Related]

  • 12. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Binkley N, Silverman SL, Simonelli C, Santiago N, Kohles JD, Dasic G, Sunyecz JA.
    Osteoporos Int; 2009 Sep 19; 20(9):1595-601. PubMed ID: 19145396
    [Abstract] [Full Text] [Related]

  • 13. Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
    Tanaka M, Hashimoto Y, Sekiya N, Honda N, Deacon S, Yamamoto M.
    J Bone Miner Metab; 2014 Jul 19; 32(4):447-54. PubMed ID: 24114194
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
    Hasegawa C, Ohno T, Umemura T, Honda N, Ohyama M, Nagase S, Small M, Deacon S, Ogawa M, Ieiri I.
    J Clin Pharmacol; 2014 Jan 19; 54(1):23-34. PubMed ID: 24115072
    [Abstract] [Full Text] [Related]

  • 15. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study.
    Engelke K, Nagase S, Fuerst T, Small M, Kuwayama T, Deacon S, Eastell R, Genant HK.
    J Bone Miner Res; 2014 Mar 19; 29(3):629-38. PubMed ID: 24038152
    [Abstract] [Full Text] [Related]

  • 16. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
    Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA.
    Clin Pharmacol Ther; 2009 Aug 19; 86(2):175-82. PubMed ID: 19421185
    [Abstract] [Full Text] [Related]

  • 17. Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women.
    Shiraki M, Sugimoto T, Nakamura T.
    Osteoporos Int; 2013 Jan 19; 24(1):219-26. PubMed ID: 23093347
    [Abstract] [Full Text] [Related]

  • 18. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
    Stone JA, McCrea JB, Witter R, Zajic S, Stoch SA.
    Br J Clin Pharmacol; 2019 Jun 19; 85(6):1072-1083. PubMed ID: 30663085
    [Abstract] [Full Text] [Related]

  • 19. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy.
    Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C.
    Eur J Clin Pharmacol; 2010 Jan 19; 66(1):29-37. PubMed ID: 19813008
    [Abstract] [Full Text] [Related]

  • 20. ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.
    Ochi Y, Yamada H, Mori H, Kawada N, Kayasuga R, Nakanishi Y, Tanaka M, Imagawa A, Ohmoto K, Kawabata K.
    J Bone Miner Metab; 2014 Nov 19; 32(6):645-52. PubMed ID: 24317478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.